Low serum adiponectin predicts 10-year risk of type 2 diabetes and HbA1c independently of obesity, lipids, and inflammation : Whitehall II study
Tabák, A. G., Brunner, E. J., Miller, Michelle A., Dr., Karanam, S., McTernan, P. G. (Philip G.), Cappuccio, Francesco P. and Witte, D. R.. (2009) Low serum adiponectin predicts 10-year risk of type 2 diabetes and HbA1c independently of obesity, lipids, and inflammation : Whitehall II study. Hormone and Metabolic Research, Vol.41 (No.8). pp. 626-629. ISSN 0018-5043Full text not available from this repository.
Official URL: http://dx.doi.org/10.1055/s-0029-1216359
Our aim of the present work was to study the effect of serum adiponectin on incident diabetes and HbA1c values. We measured baseline serum adiponectin levels in a nested case-control selection (n=140) of the Whitehall II Cohort. Participants (mean [SD] age 50.9 [6.3] years) had no prevalent diabetes or CHD at baseline. Cases (n=55) had incident diabetes according to an oral glucose tolerance test during follow-up (mean: 11.5±3.0 years). Adiponectin levels were lower among cases (9.3 μg/ml, 3.2 [median; IQR] vs. 10.5; 3.6, p=0.01). The risk of incident diabetes decreased by 11% (p=0.03) for 1 μg/ml higher adiponectin levels. Higher adiponectin levels were associated with lower HbA1c at follow-up (p<0.05). Both associations were stable to adjustment for age, sex, body mass index, systolic blood pressure, and serum lipids, and for the case of HbA1c, also for C-reactive protein (all p<0.05). The observed robust, prospective associations support that adiponectin is an independent predictor of diabetes and the degree of glycaemic impairment.
|Item Type:||Journal Article|
|Subjects:||R Medicine > R Medicine (General)|
|Divisions:||Faculty of Medicine > Warwick Medical School > Translational & Systems Medicine > Metabolic and Vascular Health
Faculty of Medicine > Warwick Medical School
|Journal or Publication Title:||Hormone and Metabolic Research|
|Publisher:||Georg Thieme Verlag|
|Official Date:||August 2009|
|Page Range:||pp. 626-629|
|Access rights to Published version:||Restricted or Subscription Access|
Actions (login required)